ArticleJournal of translational medicine2025
A macro-micro-macro radiogenomic framework identifies FIBCD1 as a key immune-modulating biomarker in breast cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBreast cancer prognosis remains challenging due to tumor heterogeneity and the limited predictive power of conventional clinical models. Integrating imaging features with molecular data may improve individualized risk stratification and clinical decision-making.
methodsWe developed a closed-loop prognostic model based on a macro-micro-macro radiogenomic framework that combines MRI-based radiomics with transcriptomic and proteomic data. A total of 788 radiomics-guided candidate genes were screened. Prognostic gene signatures were identified using multiple machine learning algorithms and validated in TCGA and GEO cohorts. We further analyzed immune infiltration, drug sensitivity, and gene enrichment profiles across risk groups. Causal relationships between gene expression and survival were assessed using Mendelian randomization. Hub gene expression was validated in patient plasma using ELISA, and Olink proteomics and radiomic information was conducted for biological association analysis.
resultsXGBoost-Cox prognostic model was constructed integrating 10 consensus genes identified by stepwise Cox regression and Elastic Net, achieving the concordance index 0.703 in GEO validation cohort. High-risk patients showed reduced immune activation, increased expression of pro-inflammatory cytokines, and worse survival. Among consensus genes, FIBCD1 was demonstrated as a hub gene with a significant causal association with survival. Its expression was significantly elevated in high-risk plasma samples, positively correlated with inflammatory proteins (e.g., OSM, and TNFSF14), and associated with MRI phenotype, including tumor sphericity and inverse difference normalized feature.
conclusionsOur findings establish a novel radiogenomic strategy that bridges MRI-derived imaging phenotypes with molecular mechanisms. FIBCD1 may serve as an immune-modulating prognostic biomarker linked to imaging characteristics, providing new insights into non-invasive breast cancer risk assessment and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.